Peak Biosciences, Inc.

Intarcia Therapeutics, Inc.

James E Matsuura

Michael J Gerber

Stephen L Warren

Catherine Manya Rohloff

Michael A DesJardin

Pauline C Zamora

Stan Lam

Kui Liu

William D Dalke

Paula Dennis

Latha Narayanan

Kevin Lillehei

Thomas A Jellison

A catheter system adapted for navigating, guiding and implanting a catheter or a plurality of catheters in a spatially-defined implantation within the tissue of a patient is provided. The system can include a tissue navigation system and a probe to inform the navigation system to guide emplacement of the catheters within a target tissue. The probe can provide images, such as fiberoptic visual images, or ultrasound images, or can provide radiolocation data, to guide the catheter emplacement. The catheters supply a pressurized liquid including a bioactive agent, such as can be used in the treatment of cancer, for example 123I- or 125I-IUDR. The system and methods provided can be used in the treatment of locally advanced tumors, such as cancers of the brain, head or neck, esophagus, prostate, ovary, liver, pancreas, bladder or rectum.

Guidance and implantation of catheters

A method is provided for treatment of disorders involving hyperproliferative cells, such as malignancies, advanced stage solid tumors like glioblastoma multiforme, and non-malignant hyperproliferative pathological conditions such as adult macular degeneration. A short range, unselective cell killing radiotherapeutic substance is administered, optionally in a spatially defined volume of tissue, optionally in combination with a mitogenic agent that stimulates or induces DNA biosynthesis. In this way, the percentage of hyperproliferative that are susceptible to killing by the radiotherapeutic agent is increased. Cancer stem cells can be induced to enter S phase with the mitogenic agent, then killed with the radiotherapeutic agent. Thus, not only does the combination effectively kill the transit amplifying cell population, the most rapidly replicating type of cell in a tumor, but it also effectively kills the tumor stem cells, which give rise to the transit amplifying cells, for a longer lasting anticancer effect.

Methods of treatment of androgenic steroidal hormone dependent cancer with auger electron-emitting nucleoside analogs

An implantable device includes a reservoir containing a suspension of an interferon in an amount sufficient to provide continuous delivery of the interferon at a therapeutically effective rate of 1 ng/day to 600 &#x3bc;g/day to maintain and achieve therapeutic blood or plasma levels of the interferon throughout a substantial period of the administration period.

Implantable device for continuous delivery of interferon

Growing community of inventors

Fort Collins, CO, United States of America

James E Matsuura